ContextVision AB presents Q4 and full year 2015 report

ContextVision: The best year in our history ContextVision, the leading provider of image processing software, has delivered a record-breaking year. Reaching the highest yearly revenues ever and topped off by very good R&D-results within artificial intelligence and deep learning.– We proudly announce that a very strong quarter ends 2015. And we have an even stronger cash position than […]
Read More

ContextVision AB – Mandatory notification of trade

Stockholm, December 23rd, 2015 Anita Tollstadius, CEO and primary insider in ContextVision AB, has between December 18th and December 23rd 2015 purchased 5 000 shares in ContextVision AB at an average price of NOK 25,67 per share. Following this transaction, Anita Tollstadius owns 5 000 shares in ContextVision AB. Anita Tollstadius also owns 10 000 shares […]
Read More

ContextVision AB: Financial calendar

Financial calendar for ContextVision AB FINANCIAL YEAR 2015Quarterly Report – Q4 – 18.02.2016 FINANCIAL YEAR 2016Quarterly Report – Q1 – 21.04.2016Quarterly Report – Q2 – 18.08.2016Quarterly Report – Q3 – 27.10.2016Quarterly Report – Q4 – 23.02.2017 Annual General Meeting – 20.04.2016 For further questions please contact CFO Ann-Charlotte Linderoth; This information is published pursuant […]
Read More

ContextVision AB – Mandatory notification of trade

Stockholm, October 30th, 2015 Karin Bernadotte, board member and primary insider in ContextVision AB, has on October 29th 2015 purchased 3 000 shares in ContextVision AB at a price of NOK 22,18 per share. Following this transaction, Karin Bernadotte owns 3 000 shares in ContextVision AB. For inquires please contact CEO Anita Tollstadius; This […]
Read More

ContextVision AB presents Q3 2015 report

22 October, 2015 Strong third quarter for ContextVision ContextVision AB (OSE: COV), the medical imaging software company, today announced its third quarter 2015 financial results. ContextVision achieved one of its best quarterly financial results ever, despite expanded R&D activity. ContextVision’s cash position was the strongest in Company history at the end of the quarter, enabling […]
Read More

ContextVision AB presents Q2 2015 report

ContextVision continues positive sales development ContextVision AB (OSE: COV), the medical imaging software company, today announced its second quarter and first half 2015 financial results. ContextVision continues its positive sales development. Revenues in the second quarter were 15 per cent higher than in the corresponding quarter last year and at par with the strong first […]
Read More

ContextVision awarded research grant to develop new technology

ContextVision AB (OSE: COV), the medical imaging software company, has together with its academic partner been awarded a research grant of € 683,000 for a research program aimed at developing new imaging technology within prostate cancer and digital pathology. The technology under development is expected to expand ContextVision’s market footprint significantly. The research program is […]
Read More

ContextVision AB Company presentation held in Oslo

Stockholm, June 18th 2015 ContextVision held a company presentation in Oslo on June 16th 2015 at 11.30 The arrangement was held at Norne Securities AS premises at Haakon VII:s gt. 9, Oslo. CEO Anita Tollstadius gave an update of the company’s development and shared the company’s future direction. Please find a PDF-version of the presentation […]
Read More

ContextVision AB: Company presentation at Avanza Bank

We would like to inform that Anita Tollstadius, CEO of ContextVision, will hold a company presentation at Avanza Banks Investor Event in Stockholm tomorrow, Wednesday, 2015-05-20. The presentation will be webcasted the same day at 14.00. Follow this link to view the webcast: A link to the presentation is also available at our website: www.contextvision.se […]
Read More

ContextVision AB Annual General Meeting

On the 22nd of April 2015, ContextVision held its ordinary Shareholders’ Annual General Meeting in Stockholm. The annual financial report regarding 2014 was presented, and approved by the AGM.  Disposition of financial results according to the proposal of the Board of Directors was approved.  The Managing Director and the Board of Directors were discharged from […]
Read More